Key Assets

Subject to US Bankruptcy Court Approval, Case # 16-11945-CSS Nuclea Biotechnologies, Inc.

Global Online Auction: Unprecedented offering of all assets of Nuclea Biotechnologies, including IP and material for the HER2, EGFR and other assays.

Nuclea Background:

Nuclea was founded in 2005 with a focus on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Nuclea’s proprietary discovery platforms and clinical research network has resulted in a collection of novel biomarkers and antibodies that filled their assay pipeline.

In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer.

Data Room Access:

We have a data room available for interested Buyers. Please contact Craig Thompson to obtain access to the data room. Email: [email protected]

Auction Lots:

Lot 1:

Materials represent hybridomas, antibodies, standards and the know-how to manufacture the FDA cleared serum HER-2 test with the CE MARK. Included is the TA-1 and NB-3 hybridomas as well as stocks of the purified TA-1 and NB-3 antibodies and the purified HER-2 material to make standards and controls for the ELISA test.

To View An Extended Description of Lot 1, please click here

To View a list of the Hybridoma Inventory for HER-2 included with lot 1, please click below:

 

For additional information about lot 1, please contact Craig Thompson for access to the data room.

 

Lot 2:

The Nuclea Biotechnologies assets include a set of hybridomas that secrete Mabs with unique specificities to various proteins in the categories of oncogenes, tumor suppressor genes, markers of metastasis, growth factor receptors,  markers of hypoxia and angiogenesis.  These Mabs can be used in a variety of formats including ELISA, IHC, Western blot, immunoprecipitation and flow cytometry. Many of these antibodies have not yet been commercialized and some Mab have therapeutic potential.

To View An Extended Description of Lot 2, please click here

To View a list of the Hybridoma Inventory included with lot 2, please click below:

 

For additional information about lot 2, please contact Craig Thompson for access to the data room.